Lupus and pesticide exposure in Martinique
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at how exposure to a pesticide called chlordecone might affect people with lupus in Martinique. Researchers want to understand if there is a link between the chemical and lupus symptoms or kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of lupus (an autoimmune disease) based on standard medical criteria.
- You must have been treated at the internal medicine department of the University Hospital of Martinique since 2005.
- Your lupus must have been active for at least 3 years.
- You need to have lived in Martinique or Guadeloupe for at least 1 year.
- You must be willing to give your written permission to take part and for your data to be used.
- You cannot currently be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This trial checks how well the drug mycophenolate mofetil works in people with lupus kidney disease by measuring drug levels in the blood. It aims to help doctors adjust doses for better control of the disease.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.